Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation
Authors' conclusion
In a real-world target trial emulation, GLP-1 receptor agonist initiation was not associated with increased risk of most psychiatric disorders compared with SGLT2i or DPP4i use, though a modest association with anxiety disorder was observed.
Study context
- Population
- Adults with T2D
- Comparison
- GLP-1 RA initiation vs SGLT2i or DPP4i use
- Outcome
- Psychiatric disorders
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
- GLP-1 RA initiation not associated with increased risk of most psychiatric disorders vs SGLT2i or DPP4i use
- Modest association with anxiety disorder observed
Original publication
Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation. Diabetes Res Clin Pract. Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →